Oncodesign offers patient-derived colorectal tumour models for drug
11 April 2011
Dijon-based Oncodesign is offering what it claims is the
world’s most comprehensive collection of human colorectal cancer models
directly developed from patient’s tumours.
Oncodesign’s clients can now access the entire collection to
evaluate therapeutic compounds in house or to carry out preclinical
studies with Oncodesign.
This new collection has integrated Oncodesign’s Chi-Mice platform,
designed to provide state-of-the-art preclinical models from human
samples. The Chi-Mice platform includes both reconstituted human
immune system models on NSG/NOG mice and models xenografted with
"This collection is the result of a five-year research program,
and is the most comprehensive worldwide in terms of the range of
genetic heterogeneity and characterization. It marks a breakthrough
in the evaluation of colorectal cancer therapies,” explained
Philippe Genne, president and CEO of Oncodesign.
"The CReMEC collection ensures low-passage experimental models to
fit the clinical reality. This is all the more relevant since
preclinical research usually relies on cell lines that may be many
years old, grown in tissue culture and then grafted onto mice. Cell
lines may drift into different genetic profiles and are not reliable
enough to evaluate anticancer therapies."
CReMEC brings together highly qualified and complementary skills
from world-class French institutes, three pharmaceutical companies,
and Oncodesign as project leader. The €5.4
million program has been developed to meet industrial requirements
and strict guidelines were observed from conception to
characterization. A full range of characterization is available with
Clinical, molecular, pharmacological and histological data have
been collected and gathered in a dedicated database, in parallel
with a biobank of more than 5,000 samples. The CReMEC collection and
derivatives represent a valued basis for Oncodesign’s clients and
academic institutions now conducting research projects with these
Based on this initial success, Oncodesign says the consortium is
considering the development of a dedicated national platform. The
challenge is to provide patient-derived cancer models for any cancer
pathology to meet unsatisfied needs in cancer research.